|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 38.03 USD | +3.20% |
|
+3.79% | +39.71% |
| 09-21 | BofA Securities Adjusts Agios Pharmaceuticals Price Target to $50 From $46, Maintains Buy Rating | MT |
| 07-30 | Agios Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.27B | - | ||||
| 63.48B | |||||
| 54.55B | |||||
| 53.59B | |||||
| 44.75B | |||||
| 41.62B |
Select your edition
All financial news and data tailored to specific country editions
